Lung Carcinoma Developing Afatinib-Associated Skin Reactions
Received Date : 20 Jun 2022
Accepted Date : 01 May 2023
Available Online : 12 Jun 2023
Doi: 10.37047/jos.2022-92025 - Article's Language: EN
J Oncol Sci. 2023;9(2):112-6
This is an open access article under the CC BY-NC-ND license
Afatinib is an irreversible second-generation tyrosine kinase inhibitor. It is used to treat epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma. The most well-known side effects associated with afatinib are diarrhea, rashes or acne and stomatitis. Herein, we present a case of skin toxicity that developed in the late phase of afatinib treatment. A 51-year-old, non-smoker woman diagnosed with EGFR deletion-19 mutant advanced lung adenocarcinoma. Afatinib was initiated as the first-line treatment. At the twelfth treatment month, Grade-2 acneiform dermatitis, paronychia, and HFS developed. Despite the interruption or discontinuation of afatinib treatment and local/systemic steroid treatments, the lesions did not regress. The patient was responsive to afatinib; however, the treatment was discontinued in the eighteenth month of treatment. The treatment response may be predicted by the severity of skin toxicities owing to afatinib. They occur in the early treatment phase and are commonly observed at the Grade 1-2 level.
  1. Joshi M, Rizvi SM, Belani CP. Afatinib for the treatment of metastatic non-small cell lung cancer. Cancer Manag Res. Feb 2015;7:75-82. [Crossref]  [PubMed]  [PMC] 
  2. Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830-838. [Crossref]  [PubMed] 
  3. Chen X, Zhu Q, Zhu L, et al. Clinical perspective of afatinib in non-small cell lung cancer. Lung Cancer. 2013;81(2):155-161. [Crossref]  [PubMed] 
  4. Dienstmann R, Bra-a I, Rodon J, Tabernero J. Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist. 2011;16(12):1729-1740. [Crossref]  [PubMed]  [PMC] 
  5. Nasu S, Suzuki H, Shiroyama T, et al. Skin rash can be a useful marker for afatinib efficacy. Anticancer Res. 2018;38(3):1783-1788. [Crossref]  [PubMed] 
  6. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101(36):13306-11. [Crossref]  [PubMed]  [PMC] 
  7. Zhang Y, Miao S, Wang F, et al. The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a systematic review and meta-analysis. J Thorac Dis. 2017;9(7):1980-1987. [Crossref]  [PubMed]  [PMC] 
  8. Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141-151. [Crossref]  [PubMed] 
  9. Park K, Tan EH, O'Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577-589. [Crossref]  [PubMed] 
  10. Melosky B. Review of EGFR TKIs in metastatic NSCLC, including ongoing trials. Front Oncol. Sep 2014;4:244. [Crossref]  [PubMed]  [PMC] 
  11. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213-222. [Crossref]  [PubMed] 
  12. Tischer B, Huber R, Kraemer M, Lacouture ME. Dermatologic events from EGFR inhibitors: the issue of the missing patient voice. Support Care Cancer. 2017;25(2):651-660. [Crossref]  [PubMed]  [PMC] 
  13. Califano R, Tariq N, Compton S, et al. Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK. Drugs. 2015;75(12):1335-1348. [Crossref]  [PubMed]  [PMC] 
  14. Razis E, Karina M, Karanastassi S, Fountzilas G. Three case reports of hand-foot syndrome with gefitinib. Cancer Invest. 2006;24(5):514-6. [Crossref]  [PubMed] 
  15. Lacouture ME, Schadendorf D, Chu CY, et al. Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther. 2013;13(6):721-728. [Crossref]  [PubMed] 
  16. Chu CY, Chen KY, Wen-Cheng Chang J, Wei YF, Lee CH, Wang WM. Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities. J Formos Med Assoc. 2017;116(6):413-423. [Crossref]  [PubMed] 
  17. Pomerantz RG, Mirvish ED, Geskin LJ. Cutaneous reactions to epidermal growth factor receptor inhibitors. J Drugs Dermatol. 2010;9(10):1229-1234. [PubMed] 
  18. Szilveszter KP, Németh T, Mócsai A. Tyrosine kinases in autoimmune and inflammatory skin diseases. Front Immunol. Aug 2019;10:1862. [Crossref]  [PubMed]  [PMC] 
  19. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327-3334. Corrected and republished in: J Clin Oncol. 2023;41(16):2869-2876. [Crossref]  [PubMed] 
  20. Fuggetta MP, Migliorino MR, Ricciardi S, et al. Prophylactic dermatologic treatment of afatinib-induced skin toxicities in patients with metastatic lung cancer: a pilot study. Scientifica (Cairo). Jan 2019 31;2019:9136249. [Crossref]  [PubMed]  [PMC]